BioCorRx Inc (OTCMKTS: BICX) On A Bull Run

BioCorRx Inc. (OTCMKTS: BICX), the distributor of alcoholism and opioid addiction treatments, has run up close to 1000% this year. Thus, we commenced an investigation to understand the real value of this company and the reasons behind this outstanding growth. We also wanted to see if there's more run room growth or if it's time to book profits. Take a look at the chart:SourceThe companyThe company is divided into two divisions: BioCorRx Pharmaceuticals and BioCorRx Recovery Program. The market for the two divisions is quite large, as opioid abuse and addiction is a devastating problem right now in America. According to the FDA, $30 billion is the total annual cost to the health care system of the alcohol addiction. Additionally, the illicit drugs’ cost annually is not small; $11 Billion. In this article, we will explain you how BioCorRx addresses these issues.BioCorRx PharmaceuticalsThis division is in charge of the development of BICX101; a long lasting injectable naltrexone. The company has partnered with Therakine to complete the development of this new drug. According to the company, the new product has numerous advantages over Vivitrol, another product developed by the company Alkermes PLC (NASDAQ: ALKS), and is already approved by the FDA. The new product BICX101 will be longer-lasting, less painful, should not require refrigeration on time to thaw, and requires lower dose volume.BioCorRx Recovery ProgramBioCorRx provides the BioCorRx Recovery Program, which helps individuals treat alcoholism and opioid addiction. According to the most recent 10-Q, the product is unique as it combines medical intervention as well as a counseling and coaching program.For those who have been following the company for some time, previously it was called Fresh Start Private Management, Inc., but it changed its name to BioCorRx Inc. on January 7, 2014. The ticker changed as well from CEYY to BICX.The BioCorRx Recovery Program is divided into different parts:

1. The administration of an implant under the skin, which is called Naltrexone. This implant can reduce alcohol and opioid cravings and certain effects over a period of several months.
2. A one to one "substance abuse disorder life coaching and counseling programs".

We found some information about how Naltrexone works in this presentation to investors, and we selected the following slides:SourceSourceWe found several interesting videos from patients and experts that say the company is helping people. This is a list of this videos:

• Fox News
• Media Channel
• Event" 2016 in Bel Air, CA.

Financial Perspective and securities outstandingThe last financial reports that the company delivered include a detailed list of the assets and liabilities of the company.These are the most important assets:

• Cash: $1,174,817
• Restricted cash: $250,000
• Intellectual property, net: $55,648
• Total assets: $1,582,609

These are the most important liabilities:

• Accounts payable: $815,846
• Deferred revenue: $432,836
• Notes payable: $518,660
• Derivative liability: $2,699,418
• Total liabilities: $6,100,454

The most important liabilities include the convertible debt and warrants, which are represented in the derivative liability. These are products that are convertible to common shares.Recent news releasedApart from the appearance of the CEO of the company on the Fox Business Network's "Mornings with Maria" that may have increased awareness of the company and may explain part of the 2017 run up pattern, we found some other news. For example, on March 21, 2017, the company announced the positive preliminary data from preclinical studies evaluating BICX101.Brady Granier, CEO, President, and Director, was quoted in the press release:

"This third round of in vivo studies has produced some very exciting results thus far. We still have a couple more weeks or so before this study is completed and the final report from Covance is delivered. What is particularly exciting about this round of data is that we have discovered that we may have two different lead formulations that may lead to 2-3 different types of products in the future. Our primary goal is to achieve a once a month injectable product in a low volume and small needle, along with many other advantages over current products, but what we discovered in the last few weeks of studies may lend itself to another possible product. We have also discovered that we can deliver two weeks of drug release in vivo in a very low volume of approximately 0.5 ml. This could lead to the possibility of a self-administered, at-home product. The implications of this can be very profound in terms of how alcohol abuse and opioid overdose protocols are amended in the future. Alcohol Use Disorder (AUD) is a much larger problem than alcohol addiction, as many abuse alcohol without necessarily being addicted. A product such as this might be used for harm reduction for those who have an alcohol use problem, but not yet full-blown addiction. In terms of opioid overdose reversal using naloxone, there could be an opportunity for a product to be administered after naloxone, which can add further protection to that individual by extending overdose protection by a couple of weeks. Of course, more investigation will need to take place for these indications, but the feedback from addiction experts on these is very positive. With regard to our main objective of the monthly injectable, we have identified at least two formulations that are releasing the drug quite nicely in vivo and we are anticipating more data points in the very short term." Source

If you had the time to read the statement, you may have noticed that the company made a new discovery and stated that the product could be used at home in the future. The company will need to keep investigating, but we believe that this news was perhaps part of the reason behind the recent run.ConclusionBioCorRx seems to be a valuable pick right now. The company is delivering interesting news about the product BICX101, which is under development. Additionally, the company is getting a lot of press in America, such as on the Fox Channel. All together, it is helping drive interest in BICX and why we think it can continue. In any case, BICX is an interesting story on the OTC Markets and one which we will be following for our subscribers.We will be updating our subscribers as soon as we know more. For the latest updates on BICX, sign up below!Disclosure: We have no position in BICX and have not been compensated for this article.